Literature DB >> 7703499

Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections.

D J Verbik1, J D Jackson, S J Pirruccello, K D Patil, A Kessinger, S S Joshi.   

Abstract

A considerable number of patients with malignancies who are treated with high-dose therapy and hematopoietic stem cell transplantation subsequently relapse. Analyses of peripheral blood stem cell (PBSC) harvests obtained from 49 cancer patients showed that the PBSC harvest contained precursors for antitumor effector cells. Ex vivo manipulation of these harvests to maximize the antitumor effector cell activity may provide a new therapeutic approach to decrease or eliminate any minimal residual disease that remains after high-dose therapy. Characterization of PBSC from consecutive collections determined the collections best suited for ex vivo augmentation of antitumor cytotoxic effector cells. We report the results of a functional and phenotypical characterization of PBSC obtained from six consecutive collections from 18 cancer patients receiving granulocyte-macrophage colony-stimulating factor (GM-CSF) for hematopoietic stem/progenitor cell mobilization. The PBSC were evaluated for their cytotoxicity using the 51Cr-release assay. The frequency and subsets of lymphocytes were determined using flow cytometry with appropriate specific marker antibodies and differential cell counts. The content of hematopoietic progenitor cells in each collection was determined using a colony-forming unit granulocyte-macrophage (CFU-GM) culture assay. The frequency of cytotoxic effector cells including lymphokine-activated killer (LAK) cell precursors and lymphocytes was significantly greater (P < .05) in the early collections, whereas the later collections contained significantly (P < .05) more CFU-GM progenitor cells and fewer cytotoxic effector cells. Thus, our results show that PBSC obtained from advanced cancer patients do contain considerable levels of precursor cells for the generation of LAK cell populations. These results suggest that cells from the earlier collections are best suited for ex vivo manipulation to augment the antitumor effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7703499

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.

Authors:  James N Kochenderfer; Jessica L Simpson; Christopher D Chien; Ronald E Gress
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

2.  In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.

Authors:  D J Verbik; W W Stinson; M J Brunda; A Kessinger; S S Joshi
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

3.  Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma.

Authors:  Ning Bu; Haiqin Wu; Bingzhong Sun; Guilian Zhang; Shuqin Zhan; Ru Zhang; Le Zhou
Journal:  J Neurooncol       Date:  2011-02-19       Impact factor: 4.130

4.  Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells.

Authors:  Avadhut D Joshi; Erin M Clark; Peng Wang; Corey M Munger; Ganapati V Hegde; Sam Sanderson; Harish P G Dave; Shantaram S Joshi
Journal:  J Neuroimmune Pharmacol       Date:  2006-10-10       Impact factor: 7.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.